Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis

Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis

[Display omitted] •Indirect comparisons yielded no differences in OS and PFS between PD-1/PD-L1 inhibitors in NSCLC.•Indirect comparisons showed higher ORR for pembrolizumab and nivolumab relative to atezolizumab.•Pembrolizumab ranked 1 st in OS/ORR and OS subgroups: adenoCa, EGFR mutant, ECOG 1, ma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical reviews in oncology/hematology 2019-10, Vol.142, p.16-25
Hauptverfasser: Almutairi, Abdulaali R., Alkhatib, Nimer, Martin, Jennifer, Babiker, Hani M., Garland, Linda L., McBride, Ali, Abraham, Ivo
Format: Artikel
Sprache:eng
Schlagworte:
Atezolizumab
Immunotherapy
Network meta-analysis
Nivolumab
Pembrolizumab
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Indirect comparisons yielded no differences in OS and PFS between PD-1/PD-L1 inhibitors in NSCLC.•Indirect comparisons showed higher ORR for pembrolizumab and nivolumab relative to atezolizumab.•Pembrolizumab ranked 1 st in OS/ORR and OS subgroups: adenoCa, EGFR mutant, ECOG 1, male, age
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2019.07.004